Workflow
半夏白术天麻颗粒
icon
Search documents
以岭药业:上半年扣非净利润增长27%,二线专利品种发力增长超50%
8月27日晚间,创新中药龙头以岭药业(002603)(002603.SZ)发布半年度报告。延续一季报业绩回暖趋势,2025年上半年公司 归母净利润同比增长26.03%,实现6.69亿元,扣非净利润同比增长27.08%,实现6.41亿元。利润回正的同时,公司也积极开展分红 以回报投资者,2025年半年度拟向全体股东每10股派发现金红利3元(含税),分红总额达5.01亿元。 专利中药产品矩阵渐成,二线专利品种加速放量 纵观中报,创新研发的投入与成果仍是公司报告期内最为突出的亮点。据披露,2025年上半年,以岭药业研发投入金额达3.99亿 元,营收占比9.87%,在中药行业中稳居前列。 具体至科研成果,在心脑血管用药优势领域,2025年6月发布的《经皮冠状动脉介入治疗指南(2025)》推荐公司旗下"通心络胶 囊"用于治疗急性冠脉综合征,8月发布的《中国心房颤动管理指南(2025)》推荐公司旗下"参松养心胶囊"用于阵发性房颤维持 窦性心律及持续性房颤射频消融术后防复发。在已有大批专家共识及治疗指南推荐的基础上,公司核心产品再获推荐,代表着医 学界对公司产品临床价值的高度认可。 不同于化药及生物制品新药上市后快速放量并 ...
以岭药业交出亮眼“成绩单”的背后:持续创新+海外市场拓展
Sou Hu Cai Jing· 2025-08-22 08:35
自进入2025年以来,以岭药业创新成果捷报频传,其申报注册的第一个经典名方品种半夏白术天麻颗粒目前已获受理;化学药品1类新药"G201-Na胶囊"也已 获批开展临床试验;芪防鼻通片更是在今年实现了国内、澳门双获批上市,有望进一步扩大销售的市场空间。那么,该企业持续保持旺盛生命力的核心秘诀 是什么?我们来深入探究一下。 图:以岭药业在研中药项目情况 并且,以岭药业的在研品种储备也十分充足。目前,其2个中药已申报生产,6个中药处于临床试验阶段,还有上百个院内制剂作为新药研发的储备力量,为 该企业保持稳定的创新产出奠定了基础。 战略赋能 以岭药业是推动中药现代化的代表性企业之一,主要经营有中药、化生药和大健康三大业务板块,中药是其收入和利润的主要贡献板块。截至目前,以岭药 业已上市专利中药17个,覆盖8大临床疾病系统,其中11个为国家医保目录产品,心脑血管系统和呼吸系统疾病用药领域仍处于行业领先地位,市场占有率 较高。 以岭药业始终将科技创新视为企业发展的核心竞争力,结合临床需求,持续研发惠民好药。从创新效率来看,自2020至2024年间,全国获批上市的1.1类中 药新药年均不足10个,但以岭药业在这5年间研发上市 ...
A股公告精选 | 智元机器人股权收购尚不确定 2连板上纬新材(688585.SH)提示风险
智通财经网· 2025-07-10 12:23
Group 1 - Jiangfeng Electronics plans to raise no more than 1.95 billion yuan for the production of 12,300 ultra-pure metal sputtering targets for integrated circuits and other projects [1] - Northern Rare Earth has adjusted the trading price of rare earth concentrates to 19,109 yuan per ton for Q3 2025, reflecting a 1.5% increase from the previous price [2] - Baogang Co. also plans to adjust the trading price of rare earth concentrates to 19,109 yuan per ton for Q3 2025, indicating a 1.5% increase [3] Group 2 - Shijia Photon intends to acquire 82.3810% equity of Fokexima through a combination of share issuance and cash payment, aiming to enhance its production capabilities and reduce costs [4] - Yiling Pharmaceutical's application for the registration of Banxia Baizhu Tianma granules has been accepted, marking its first classic prescription product [5] - Liangpinpuzi's controlling shareholder is planning a change of control, leading to a temporary suspension of its stock [6] Group 3 - Qin'an Co. plans to acquire 99% equity of Yigao Optoelectronics through share issuance and cash payment, with stock resuming trading [7] - Goldwind Technology's shareholder, Harmony Health, intends to reduce its stake by up to 1% within three months [8] Group 4 - Tianbao Infrastructure expects a net profit of 90 million to 130 million yuan for the first half of the year, representing a year-on-year increase of 1581.80% to 2329.27% [10] - Guosheng Jinkong anticipates a net profit of 150 million to 220 million yuan for the first half of the year, a year-on-year growth of 236.85% to 394.05% [10] - China Shipbuilding expects a net profit of 2.8 billion to 3.1 billion yuan for the first half of the year, reflecting a year-on-year increase of 98.25% to 119.49% [10]